Breaking News

Gemini Bio Acquires ORFLO Technologies

Enhances offerings in the cell and gene therapy markets

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gemini Bioproducts, LLC, a provider of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC, has acquired ORFLO Technologies, an innovative life sciences instrumentation company. Founded in 2003 by Ted Ayliffe, Ph.D., ORFLO is a supplier of cell analysis instruments including flow cytometers and cell counters, as well as their associated consumables and reagents. ORFLO’s two flagship products are the Moxi Z, a cell counter, and the Moxi Go, a benchtop flow cyto...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters